Brentuximab vedotin

Drug Profile

Brentuximab vedotin

Alternative Names: Adcetris; cAC10-vcMMAE; SGN-35

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator Seattle Genetics; Stanford University
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Fondazione Italiana Linfomi; Lymphoma Academic Research Organisation; Massachusetts General Hospital; Seattle Genetics; Stanford University; Takeda; Takeda Oncology
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease; Non-Hodgkin's lymphoma; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Hodgkin's disease
  • Phase III Cutaneous T cell lymphoma; T cell lymphoma
  • Phase II Diffuse large B cell lymphoma; Germ cell and embryonal neoplasms; Mesothelioma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome; Systemic lupus erythematosus
  • Phase I Graft-versus-host disease
  • Discontinued Leukaemia; Multiple myeloma; Solid tumours

Most Recent Events

  • 15 Jun 2017 Interim efficacy and adverse events data from a phase I/II trial in Hodgkin's disease released by Seattle Genetics and Bristol-Myers Squibb
  • 09 May 2017 Bristol-Myers Squibb plans the CheckMate 812 phase III trial for Hodgkin's disease (Monotherapy, Combination therapy, Refractory metastatic disease, Second-line therapy, Late-stage disease) in USA, Australia, Czechia, Hungary, Italy and Turkey (NCT03138499)
  • 05 Apr 2017 Phase-II clinical trials in Mesothelioma in USA (IV) (NCT03007030)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top